AstraZeneca
AZN
1,385 hedge funds and large institutions have $152B invested in AstraZeneca in 2026 Q1 according to their latest regulatory filings, with 293 funds opening new positions, 500 increasing their positions, 500 reducing their positions, and 294 closing their positions.
227% more funds holding in top 10
Funds holding in top 10: 22 → 72 (+50)
227% more capital invested
Capital invested by funds: $46.4B → $152B (+$105B)
32.57% more ownership
Funds ownership: 16.26% → 48.84% (+33%)
0% more repeat investments, than reductions
Existing positions increased: 500 | Existing positions reduced: 500
0% less first-time investments, than exits
New positions opened: 293 | Existing positions closed: 294
2% less funds holding
Funds holding: 1,408 → 1,385 (-23)
41% less call options, than puts
Call options by funds: $856M | Put options by funds: $1.45B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
Investor AB
Stockholm,
Sweden
|
+$9.95B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$5.36B |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$5.23B |
| 4 |
Legal & General Group
London,
United Kingdom
|
+$4.96B |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.6B |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$932M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$609M |
| 3 |
Fayez Sarofim & Co
Houston,
Texas
|
-$391M |
| 4 |
Harris Associates
Chicago,
Illinois
|
-$343M |
| 5 |
WCM Investment Management
Laguna Beach,
California
|
-$246M |
AZN Hedge Fund Activity: Q1 2026 in Review
1,385 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2026, worth a combined $152B — up 227% from $46.4B a quarter earlier.
Sellers outnumbered buyers: 294 funds closed out of AZN and 293 opened new positions — a net loss of 1 holder — while 500 trimmed existing stakes and 500 added.
The largest buyer was Investor AB, opening a new position worth an estimated $9.95B. The largest seller was T. Rowe Price Associates, cutting an estimated $932M.
- 1,385 institutional investors held AstraZeneca (AZN) as of Q1 2026, down from 1,408 in Q4 2025.
- Funds reported $152B of AstraZeneca stock for Q1 2026, up 227% quarter-over-quarter.
- 293 funds opened new AstraZeneca positions in Q1 2026 and 294 closed out, a net change of -1 holder.
- The largest AstraZeneca buyer in Q1 2026 was Investor AB, an estimated $9.95B added.
- The largest AstraZeneca seller in Q1 2026 was T. Rowe Price Associates, an estimated $932M sold.
Based on aggregated 13F filings for Q1 2026.